Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2018 | Ibrutinib plus obinutuzumab/venetoclax in R/R MCL: OAsIs results

Simon Rule • 18 Dec 2018
ASH 2018
Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Ibrutinib Obinutuzumab Venetoclax
OAsIs

Drug resistance in mantle cell lymphoma (MCL) is highly dependent on BCR signaling and the microenvironment. Here, Simon Rule, MD, of Plymouth University, Plymouth, UK, discusses the OAsIs Phase I trial (NCT02558816), which was designed to assess the safety, tolerability and efficacy of ibrutinib/obinutuzumab, and ibrutinib plus obinutuzumab/venetoclax, with hopes to tackle this resistance in relapsed/refractory MCL. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Rule reveals that as well as having no dose-limiting toxicities, treatment was well tolerated and provided a high level of disease control.

More from Simon Rule

Real-world results in the UK for ibrutinib at first relapsed for MCL
0:48
Real-world results in the UK for ibrutinib at first relapsed for MCL
Simon Rule • 7 Dec 2019
OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCL
1:30
OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCL
Simon Rule • 7 Dec 2019
Impressive results for R-BAC post BTKi in R/R MCL
1:28
Impressive results for R-BAC post BTKi in R/R MCL
Simon Rule • 7 Dec 2019
Long-term ibrutinib outcomes vs. prior regimens: pooled analysis in R/R MCL
1:35
Long-term ibrutinib outcomes vs. prior regimens: pooled analysis in R/R MCL
Simon Rule • 6 Dec 2019

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals